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Summary 
In the era of modern vaccinology, limited immunogenicity of the most commonly used 
antigens has enforced the use of various adjuvants in vaccine formulations to achieve desired 
immune response. Aluminum-containing adjuvants have been, historically, the most widely 
used mineral immunostimulants, generally regarded as safe to use in human vaccines. The great 
academic progress in inorganic (nano)materials synthesis, structure control and 
functionalization design has led to a growing interest in innovative adjuvants such as clays, 
mesoporous silica nanoparticles, zinc oxide, iron oxide and iron hydroxide nanoparticles, etc. 
On the other hand, there has been an intention to use specific nanoparticulated antigen delivery 
systems, such as nanoemulsions, in order to protect antigens from premature proteolytic 
degradation and/or to improve antigen immunogenicity by facilitating antigen uptake and 
processing by antigen presenting cells. Simultaneously, numerous research efforts have been 
focused on the development of innovative technologies for antigen delivery into the skin (such 
as microneedles), with the aim to improve vaccine efficacy alongside with enhanced patient 
adherence, particularly in children population (noninvasive or minimally invasive 
administration). Therefore, this review deals with each of these approaches in more detail, with 
the special emphasis on examples of their use in vaccine formulations as well as on the factors 
influencing their efficacy and safety. 
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It has been well established that effective and safe vaccines present an 
irreplaceable tool continually contributing to public and animal health worldwide, while 
the ongoing development of vaccines points out to the certain technological 
achievements during the last decades of biomedical research advancement (1). 
Currently, European Pharmacopoeia (supplement Ph. Eur. 9.8) counts 144 monographs 
of different types of vaccines intended for human and veterinary use, from which 64 
monographs are those for application in human population (2). In accordance with Ph. 
Eur. 9, Vaccines for human use (Vaccina ad usum humanum) are biological products 
that represent preparations containing antigens capable of inducing a specific and active 
immunity in man against an infecting agent, or the toxin or antigen elaborated by it. 
Immune responses include the induction of the innate and adaptive (cellular, humoral) 
parts of the immune system. Vaccines for human use have been shown acceptable 
immunogenic activity and safety within the human population taking into account the 
vaccination schedule (2). 
Further, within the general monograph, the European Pharmacopoeia describes 
types of vaccines intended for human use and their different characteristics including 
basic principles of their production. Thus, vaccines for human use may contain: whole 
micro-organisms (MOs) (bacteria, viruses or parasites), inactivated by chemical and 
physical means that maintain adequate immunogenic properties; whole live MOs that 
are naturally avirulent or that have been treated to attenuate their virulence whilst 
retaining adequate immunogenic properties; antigens extracted from MOs or secreted 
from MOs or produced by genetic engineering or chemical synthesis. The antigens may 
be used in their native state or may be detoxified or modified by chemical or physical 
means, and may be aggregated, polymerised or conjugated to a carrier in order to 
enhance their immunogenicity. Vaccines may contain some specific adjuvant or 
adjuvants. Where the antigen is adsorbed on a mineral adjuvant, the vaccine is referred 
to as „adsorbed” (2). Ph. Eur. 9 differs following types of vaccines: 1) Bacterial 
vaccines containing whole cells; 2) Bacterial vaccines containing bacterial components; 
3) Bacterial toxoids; 4) Viral vaccines; 5) Synthetic antigen vaccines; 6) Combined 
vaccines and 7) Adsorbed vaccines (2).  
Whatever the vaccine type is, vaccines authorized for the human use are clear, 
colourless liquids or they may be coloured or vary in opacity according to the type of 
preparation; further vaccines' formulation may be suspension of various degree of 
opacity in colourless liquid, or they may be powders produced by freeze-
drying/lyophilization procedure, which should be reconstituted by convenient vehicle 
just before the administration (2). In the most cases, vaccines are intended for parenteral 
administration route (intradermal vaccines), when they must be sterile, but they are also 




intranasal administration by U.S. Food and Drug Administration (FDA) in 2003 and 
intended for human population aged 5 – 49 years) (3). Besides, a series of intensive 
researches, including clinical trials, are ongoing in order to investigate and consequently 
to enable the application of vaccines using a transdermal route and generally skin 
pathways mainly involving the concept of microneedles, or sublingual as well as buccal 
routes and inhalation pathways. In their formulations, vaccines usually contain different 
pharmaceutical excipients, at the first place adjuvants and adsorbents (as a specific type 
of adjuvants), some stabilizers, buffers or preservatives (2, 3). 
Although the modern vaccines are formulated in such way to possess an 
acceptable safety profile as much as possible, thanked to the refined purification 
techniques and well defined nature of antigens, it could be happened that due to the high 
level of purity and specificity, resulted antigens have less immunogenicity (1, 4). 
Therefore, the investigation of more effective and specific adjuvants and their 
incorporation into vaccines' formulations has become a standard consideration during 
their development. 
Adjuvants are substances that when mixed with vaccines antigens, may impact 
through certain aspects to the enhancement of the immune responses: enabling sustained 
release of the given antigen dose, or allowing the antigen dose sparing, which can 
dramatically reduce vaccine-manufacturing costs; some of the adjuvants can adjust the 
vaccine formulation and make them particularly relevant to the elderly, young children 
and patients with chronic diseases (1). Emulsion systems of oil-in-water type (e.g. 
MF59 composed of squalene and two surfactants, Tween 80 and Span 85) and mineral 
components – adsorbents (aluminum hydroxide, aluminum phosphate and amorphous 
aluminum hydroxyphosphate sulfate) are used as common choice for vaccine adjuvants. 
Simulateously, there is an intention to apply specific advanced antigen- delivery 
systems (e.g. microneedles) which may improve an antigen immunogenicity, i.e. a 
vaccine efficacy alongside with adherence increase, particularly in children population 
(noninvasive or minimally invasive administration). The prospective aims of 
nanopartuculate systems as antigen carriers (nanoparticle-based vaccines) are based on 
assumptions that they could protect antigens from premature proteolytic degradation, 
facilitate antigen uptake and processing by antigen presenting cells, enable control 
release and should be safe for human use (5). Nanocarriers composed of lipids, proteins, 
metals or polymers are in focus and there is a need for some modification/adjustment of 
the critical attributes to functionalize them in order to reach an effective antigen 
delivery and satisfying immune response. In addition, it is of great importance to 
improve the performance of mineral adjuvants/adsorbents, through usage of micro- and 
mesoporous aluminosilicates. Apart different types of nanoparticulate carriers known as 
useful drug delivery systems, and therefore are considered for longer as prospective 




antigen release and penetration/permeation through the skin applying solid or soluble 
microneedles is a subject of this review (4, 5).  
2. Inorganic compounds as vaccine adjuvants 
Aluminum-containing adjuvants, as representatives of inorganic compounds, have 
been historically served as immunostimulants in vaccines and continue to be the most 
widely used adjuvants (6) generally regarded as safe to use in human vaccines (7). 
During the last decade, great academic progress in inorganic nanomaterials for vaccine 
adjuvants in terms of nanometer-scale synthesis, structure control, and functionalization 
design was achieved (8). The following section summarizes the structure, physico-
chemical and functional properties of currently used mineral adjuvants, relevant for 
their application in vaccine formulation. Additionally, a brief review of other mineral 
materials and novel inorganic nanoparticles which have been investigated as possible 
antigen carriers and adjuvants for vaccines is presented.  
2.1 Mineral Adjuvants 
Aluminum compounds and calcium phosphate are representatives of inorganic 
mineral compounds, which have been applied as immunological adjuvants in vaccine 
formulation. Of these two, the aluminum compounds have the longest history and by far 
the most comprehensive record of use (7).  
Aluminum salts, as representatives of mineral adjuvants, have been used in human 
vaccines for over 70 years. Table I summarizes examples of available vaccines currently 
licensed for human use that employ aluminium adjuvants. A.T. Glenny and coworkers 
were the first to demonstrate the adjuvant effect of aluminum compounds (9). The first 
aluminum-adjuvanted vaccines were prepared by the addition of base to a solution of 
antigen (diphtheria toxoid) mixed with aluminum potassium sulfate, resulting in 
precipitation of the antigen and aluminum salt. Glenny observed that injecting the 
diphtheria toxoid as an alum precipitate led to a significant increase in the immune 
response against the toxoid. Although the term alum is used colloquially to refer to all 
aluminum adjuvants, it is technically name for aluminum potassium sulfate 
[AlK(SO4)2ꞏ12H2O], which has not been widely used as an adjuvant in human vaccines 
(10). Vaccine preparation in accordance with this principle referred to as alum-
precipitated vaccines, has been almost completely replaced by the adsorption of 
antigens onto preformed aluminum gels referred as aluminium-adsorbed vaccines, since 
this method provides a more reproducible production process, control of the adsorption 







Table I  Examples of licensed aluminium-adjuvanted vaccines for human use (6, 9, 16) 
Tabela I  Primeri odobrenih vakcina sa adjuvansima na bazi aluminijuma za humanu upotrebu  
 (6, 9, 16) 
 
Adjuvant  Vaccine  Trade name Manufacturer 
Aluminum hydroxide  TdaP  Boostrix® GSK 
 DTaP Infanrix® GSK 
 DTaP, Hepatitis B, polio Pediatrix® GSK 
 DTaP, polio Kinrix® GSK 
 Human papilloma virus Cervarix® GSK 
 Hepatitis A Havrix® GSK 
 Hepatitis B Engerix® GSK 
 Meningococcus B Bexsero® GSK 
Aluminum phosphate 
Tetanus and Diphtheria Toxoids, 
Adsorbed 
Tenivac® Sanofi-Pasteur 
 Pneumococcus Prevnar 13® Pfizer 
 Meningococcus B Trumenba® Pfizer 
 DTaP Daptacel® Sanofi-Pasteur 




Human papilloma virus Gardasil® Merck 
 Hepatitis A VAQTA® Merck 








Hepatitis A and Hepatitis B Twinrix® GSK 
Legend: TdaP (tetanus toxoid & reduced diphtheria toxoid & acellular pertussis); DTaP 
(diphtheria toxoid & tetanus toxoid & acellular pertussis)  
 
Aluminum compounds used in the lincensed vaccines (Table I) are aluminum 
hydroxide, aluminum phosphate and amorphous aluminum hydroxyphosphate sulfate, 
although these commonly used names are scientific misnomers (6). They have 
distinctive physicochemical properties, which have important implications for their 
immunomodulatory effects (11, 12). These adjuvants are prepared in house by vaccine 
companies or purchased from manufacturers by their tradenames, such as Alhydrogel®, 




Aluminum hydroxide adjuvant and aluminum phosphate adjuvant are composed 
of very small primary particles. However, the primary particles form aggregates that are 
the functioning units in vaccines (11). Commercially available aluminum hydroxide 
adjuvant is not Al(OH)3, but rather a crystalline aluminum oxyhydroxide AlO(OH) with 
mineralogical name of boehmite, as confirmed by X-ray diffraction and infrared 
spectroscopy. This difference is important because crystalline aluminum hydroxide has 
a low surface area (approximately 20 to 50 m2/g) and as such a poor adsorbent 
properties, while crystalline aluminum oxyhydroxide has a surface area of 
approximately 500 m2/g, which makes it an excellent adsorbent. This high surface is a 
result of its morphology, since the primary particles of adjuvant are fibers with average 
dimensions of 4.5  2.2  10 nm. Aluminum oxyhydroxide is a stoichiometric 
compound, and it is composed of Al-OH and Al-O-Al groups. The Al-OH surface 
groups can accept or donate a proton, resulting in a positive or in a negative surface 
charge, which may affect the surface characteristics of this adjuvant (6).  
Aluminum phosphate adjuvant is a chemically amorphous aluminum 
hydroxyphosphate [Al(OH)x(PO4)y] in which some of the hydroxyl groups of aluminum 
hydroxide are replaced by phosphate groups. The disordered, amorphous state is 
responsible for the high surface area and high adsorptive capacity of this adjuvant 
whose plate-like particles have a diameter of approximately 50 nm (11, 12). The 
nanoparticles of this aluminium adjuvant form loosely connected porous aggregates that 
vary in size from 1 to about 20 μm depending on the adjuvant, the method used for 
measurement of particle size, and the experimental conditions (13, 14). Another 
commercially available adjuvant is amorphous aluminum hydroxyphosphate sulfate, 
which contains residual sulfate residues because alum was used instead of aluminum 
chloride for its synthesis. Transmission electron microscopy revealed mesh-like 
structure of aluminum hydroxyphosphate sulfate (15).  
Depending on the types of aluminum salts, their surface charges have notable 
differences (16). The isoelectric points (IEPs) of these adjuvants are 4.6–5.6, 7.4 and 
11.1 for aluminum phosphate, aluminum hydroxyphosphate sulfate and aluminum 
hydroxide, respectively (9, 15). Under physiological conditions (pH = 7.4), aluminum 
hydroxide is positively charged, whereas aluminum phosphate, and aluminum 
hydroxyphosphate sulfate are negatively charged (6, 9, 11), which can be of great 
significance for interaction with antigen.  
The size of the aggregate adjuvant particles can be decreased (i.e. during exposure 
to shear forces and ultrasonication (13) or increased when these particles are suspended 
in saline solution (14). The morphology of aluminum-containing adjuvants contributes 
to the uniform distribution of antigen in vaccines (11). The adjuvant aggregates undergo 
a de-aggregation and re-aggregation process during mixing. These de-aggregation and 




or combination vaccines throughout all of the adjuvant aggregates in the vaccine. Thus, 
even though quantities of antigen as low as 10 μg are combined with quantities of 
adjuvant up to 0.85 mg Al during the production of a vaccine, the nature of the adjuvant 
aggregates provides a mechanism to uniformly distribute the antigen as long as 
adequate mixing procedures are followed (11). During storage at room temperature, 
aluminum adjuvants become more ordered due to deprotonation and dehydration. Once 
the physical properties of the adjuvant are known, an antigen interaction with the 
adjuvant can be determined (17). As a general rule, the antigen should be adsorbed onto 
the adjuvant prior to immunization and the adsorption should be carefully monitored 
(7). Adsorption of antigens to aluminum adjuvants may contribute directly to the 
immune-enhancing effect of aluminum adjuvants. In addition, adsorption to the 
adjuvant may prevent adsorption of antigens to the wall of the vial or syringe, thus 
ensuring injection of the full dose of antigen (9). Owing to the complex structure of 
antigens, it is not surprising that a number of attractive mechanisms may contribute to 
their adsorption (11). These mechanisms include electrostatic attraction, hydrogen 
bonding, hydrophobic interactions, ligand exchange and van der Waals forces (11, 17), 
while each binding force in a given antigen-adjuvant combination depends on the nature 
of the antigen and the chemical environment: pH, ionic strength, presence of 
surfactants, etc. (7). The surface hydroxyls of aluminum hydroxide adjuvant provide the 
basis for the major mechanisms of adsorption of antigens: electrostatic adsorption when 
the antigen and adjuvant have opposite charges and ligand exchange when the antigen 
contains a phosphate group that is able to exchange with a hydroxyl group at the surface 
of the adjuvant. Electrostatic attraction is probably the most frequently used adsorption 
mechanism, while ligand exchange produces the strongest adsorption (6).  
Determination of antigen adsorption capacity of the adjuvant is highly 
recommended and it can be completed by a variety of analytical methods. It is usually 
done by comparing the protein content in the aqueous phase of the antigen solution 
before and after adsorption onto the adjuvant. The amount of protein in the supernatant 
is simply subtracted from the amount that was initially added, to determine the amount 
adsorbed (7, 9). The adsorption of protein antigen has been typically analyzed according 
to the Langmuir adsorption model, which enables calculation of several adsorptive 
parameters, including the adsorptive coefficient, which corresponds to the strength of 
the antigen−adjuvant interaction. In order to correct the limitations of the Langmuir 
isotherm, other models (e.g. Toth isotherm, a hybrid model combining the Langmuir 
and the Freundlich isotherms) were later developed, that are better suited to fit data 
from heterogeneous systems (7).  
2.2 Formulation of vaccines with aluminium adjuvants 
When formulating a vaccine with aluminium-containing adjuvants, it is important 




with the surface (17). Therefore, detailed characterization of aluminum-containing 
adjuvants with reference to properties that affect adsorption, such as surface area, 
surface charge, chemical composition, structure and morphology, stability, with other 
colloidal behavior is essential for consistent adjuvant effect (18, 19). Quality 
specifications for aluminium adjuvants usually list parameters based on compendial 
testing of identity, strength, purity, etc., according to their pharmacopoeial monographs 
(Table II).   
 
Table II  The tests listed in general monographs (Ph. Eur. 9.0) of aluminium hydroxide  
 adjuvant 
Tabela II  Ispitivanja navedena u opštoj monografiji (Ph. Eur. 9.0) aluminijum hidroksida kao  
 adjuvansa 
 
Aluminum hydroxide, hydrated, for adsorption 
(Aluminii hidroxidum hydricum ad adsorptionem) 




pH  5.5 – 8.5 
Adsorption power + 
Sedimentation + 
Chlorides ≤ 0.33% 
Nitrates ≤ 100 ppm 
Sulfates ≤ 0.5% 
Ammonium ≤ 50 ppm 
Iron ≤ 15 ppm 
Bacterial endotoxins Less than 5 IU of endotoxin per milligram of 
aluminium, if intended for use in the 
manufacture of an adsorbed product without a 
further appropriate procedure for the removal 
of bacterial endotoxins.  
Assay 90 – 110% 
Storage: at a temperature not exceeding 30 C. Do not allow to freeze. If the supstance is a 
sterile, airtight, tamper-proof container.  




Care must be taken in selecting a buffer for an aluminum hydroxide adjuvant–
containing vaccine (6). Phosphate anions are adsorbed by both aluminum hydroxide 
adjuvant and aluminum phosphate adjuvant by ligand exchange (19). Although the 
adsorption of antigens onto aluminum adjuvants is heavily dependent on electrostatic 
attraction, ligand exchange occurs with phosphorylated antigens and is the strongest 
adsorption force (10). The adsorption of phosphate anion present in a vaccine 
formulation as buffer can affect the adsorption of an antigen by affecting both the 
surface charge and the number of surface hydroxyls available for ligand exchange with 
phosphate groups of the antigen (19). Iyer et al. (20) determined the extent (adsorptive 
capacity) and strength (adsorptive coefficient) of adsorption for three phosphorylated 
proteins (alpha casein, dephosphorylated alpha casein, and ovalbumin), by the 
phosphate-treated aluminum hydroxide adjuvants, and found that it was inversely 
related to the degree of phosphate substitution of the aluminum hydroxide adjuvant. It is 
recommended that exposure of vaccines containing aluminum hydroxide adjuvant and 
phosphorylated antigens to phosphate ion in the formulation or during manufacture, 
should be minimized to produce maximum adsorption of the antigen. Therefore, 
phosphate buffer should be avoided in the formulation of vaccines with aluminium 
adjuvants, unless there is a specific rationale for its use (9).  
Other anions of commonly used buffers that can affect adsorption include citrate, 
carbonate and succinate (9). Citrate buffer may lead to an increase in the soluble 
aluminum concentration. It was demonstrated that the citrate anion in an α-
hydroxycarboxylic acid adsorbs to an aluminum-containing adjuvant and solubilizes the 
aluminum by formation of a soluble aluminum–citrate complex. Buffers that do not 
appear to alter the properties of aluminium-containing adjuvants include acetate, 
histidine, MOPS (3-(N-morpholino) propanesulfonic acid) and TRIS (tromethamine) 
buffers (6, 9, 19). Vaccines should be isotonic to reduce pain upon parenteral 
application; therefore, addition of excipients to adjust the tonicity is necessary. It has 
been demonstrated that ionic strength of sodium chloride solution can reduce the 
adsorption of electrostatically adsorbed adjuvants (21), so it is more appropriate to use a 
polyol rather than sodium chloride to adjust the tonicity of a vaccine containing 
electrostatically adsorbed antigen (11). Surfactants are frequently added to vaccine 
formulations to increase antigen stability. It was reported that nonionic surfactant 
produced less elutability of proteins from aluminium adjuvants in model vaccines 
compared to anionic and cationic surfactants. Although it is likely that nonionic 
surfactants such as polysorbate 20 and polysorbate 80 also do not affect the adsorption 
of antigens on aluminum hydroxide and phosphate, this needs to be further evaluated 
(9).  
Aluminum hydroxide adjuvant and aluminum phosphate adjuvant both exhibited 




adsorption capacity. Therefore, autoclaving conditions should be selected minimizing 
exposure time to elevated temperatures, and procedures requiring repeated autoclaving 
of the same samples should be avoided (19).  
Vaccines adjuvanted with aluminum salts are formulated as liquid suspensions 
and must remain stored in cold chain at 2–8 °C from manufacturing to being 
administered to patients, due to aluminium adjuvant sensitivity to freezing and freezing 
induced irreversible coagulation or aggregation of the gel particles (10, 22). Vaccines 
containing aluminum hydroxide adjuvant or aluminum phosphate adjuvant should not 
be allowed to freeze and should not be used if suspected of having been exposed to 
freezing temperatures (6, 23). Aluminum salts are suspensions of hydrated colloid 
particles with slow sedimentation in water due the oriented water molecules that give 
buoyancy and the charges on the salts, enabling electrical repulsion among the particles 
in the suspension (10). Freezing brings changes in the structure and morphology of the 
adsorbed vaccines, whether monovalent or combined. It has been proposed that ice 
crystals formed during freezing force aluminum particles to overcome repulsion, 
thereby producing strong interparticle attraction resulting in aluminum particle 
coagulation/agglomeration. Thus, this particles agglomerates become bigger and 
sediment faster than particles in non-frozen vaccines. The size of the agglomerates 
seems to increase on repeated freezing and thawing cycles. Adsorbed vaccines kept at 
the optimal temperature (2–8 °C) show a fine-grain structure. In contrast, large 
conglomerates of massed precipitates with a crystalline structure are observed in 
vaccines affected by freezing (23). During the last two decades several technologies 
have been developed to overcome aluminium salt-adjuvanted vaccines sensitivity to 
freezing conditions (10, 22, 24).  
Calcium phosphate was initially developed by the Pasteur Institute in 
hydroxyapatite form (Ca10(PO4)6(OH)2). X-ray diffraction, Fourier transform infrared 
spectroscopy, and thermal analysis of commercially available calcium phosphate (from 
Reheis Inc. NJ, USA) indicated that calcium phosphate adjuvant, with the suggested 
formula of Ca3(PO4)2, could be described as nonstoichiometric hydroxyapatite, Ca10-
x(HPO4)x(PO4)6-x(OH)2-x, where x varies from 0 to 2 (7). Calcium phosphate was used as 
an adjuvant in diphtheria, tetanus, pertussis and poliomyelitis vaccines in France, but it 
was completely substituted by alum salts in the late 1980s. However, it still remains as 
an approved adjuvant for the World Health Organization for human vaccination 
(1,4,25), EMA (4) and Ph. Eur. (1). Adsorption capability of calcium phosphate is 
similar to aluminium adjuvants, and it depends on preparation method (concentration of 
reactants and rate at which the reactants are mixed), Ca/P ratio, presence of hydroxyl 
groups, zeta potential and specific surface. The point of zero charge of calcium 
phosphate is 5.5, so it has a good adsorption capacity of positively charged and 




even at a nanoscale. According to Masson et al. (25), within the next 5 years, studies 
and clinical trials necessary for the calcium phosphate reuse in human vaccination could 
be completed. This wider range would enable patients to choose an adjuvant, thus 
ensuring a great vaccinal coverage. 
In the general monograph „Vaccines for human use” (Ph. Eur. 07/2018:1053) 
aluminium (Al) content is maximum 1.25 mg per human dose, unless otherwise stated 
(1). In the United States, the limit is 0.85 mg aluminum per dose if determined by assay, 
1.14 mg if determined by calculation on the basis of the amount of aluminum compound 
added, and 1.25 mg if safety and efficacy data justify it (9). The maximum allowed 
amount of calcium (Ca) is 1.3 mg per human dose, unless otherwise stated (1). 
2.3 Novel inorganic nanoadjuvants as potential antigen carriers and vaccine 
      adjuvants 
Application of clay minerals in drug delivery has been intensively investigated in 
last two decades due to their advantagenous physico-chemical and functional properties, 
such as high specific surface area, adsorption, and ion exchange, thixotropy, swelling 
property, chemical inertness, low toxicity and possibility of surface modification (26–
28). Additionally, clays have been recognized as alternative immunogen support in 
vaccine formulations due to their ability to increase the stabilization of immunogens 
that can enable easier administration and protection from proteolysis, and improved 
thermal and storage performance. However, it has also been observed in several studies 
that adsorption of antigens on pristine clays can alter their protein structure which can 
result in decayed immunogenicity of the antigen and eventually compromise the 
vaccination efficacy (29, 30). In order to overcome important issues related to the 
thermostability of vaccines and stability problems related to accidental freezing during 
transportation and storage, sepiolite-lipid bio-nano hybrids as novel adjuvants in 
thermostable influenza A vaccines were explored. In brief, these hybrids were obtained 
by modification of sepiolite fibres (Pangel S9 from Tolsa S.A., Spain) with a bilayer 
lipid membrane by contacting a 0.2 wt% sepiolite suspension with a 0.8 mM liposome 
dispersion. Liposomes were prepared from phosphatidylcholine (EmulmetikTM, Lucas 
Mayer GmbH, Germany) by the extrusion method (31). Improved thermal stability 
within functional studies at elevated temperatures up to 48 C was shown with enhanced 
resistance against lyophilization-induced antigen denaturation as often seen for alum-
stabilized antigens (32). This improvement in thermal stability was suggested to be 
related to creation of a chemical microenvironment by the sepiolite–lipid biohybrid 
forming a somewhat thermally protective scaffold for the adsorbed influenza virions. 
Fujimori et al. (33) fabricated ultrathin multilayer films of adsorbed biological 
molecules (enzyme lysozyme) by means of the modified Langmuir–Blodgett method 
using an organo-modified aluminosilicate (dimethyldioctadecylammonium modified 




sensitive biological species was reported since surprisingly high thermal stability of 
lysozyme showing enzymatic activity until 160 C was determined. Clay nanoparticles, 
for example, layered double hydroxide (LDH) and hectorite nanoparticles, have shown 
their potent adjuvanticity in generating effective and durable immune responses in 
animal models. These findings suggest that both clay nanoadjuvants can serve as active 
vaccine platforms for sustained and potent immune responses (34). 
The use of mesoporous silica nanoparticles (MSNs) has gained significant 
attention as potential delivery vehicles for various biomolecules (35). The main 
advantages of these materials are well-defined surface properties, high porosity, large 
surface area, low density, excellent biocompatibility, thermal and chemical stability (36, 
37). It has been shown that introduction of MSNs as an immunoadjuvants can 
effectively enhance both cellular and humoral immunity in animal models (8, 38, 39). 
The factors like nanoparticle architecture, antigen type, antigen loading/encapsulation, 
dose administered, and immunization route can influence the adjuvant properties of 
MSNs (35). The capacity of MSNs to induce both humoral and cell mediated immune 
responses over traditional adjuvants is a great advantage, and in the future, more studies 
are expected to evaluate the biocompatibility, stability, efficacy and biological 
interactions of MSNs based protein delivery system (40). Other representatives of 
inorganic nanoparticles such as zinc oxide, iron oxide and iron hydroxide, cobalt oxide, 
titanium dioxide, nanodiamond, luminescent porous silicon, guantum dots have been 
also in focus of academic research towards next-generation vaccines (8). In the past few 
years, numerous studies have also demonstrated the great potential of nanoparticles of 
metal-organic frameworks (nanoMOFs) at the preclinical level for biomedical 
applications, among other as vaccine adjuvant delivery systems (41). 
3. Nanotechnology in the development of vaccine adjuvants 
In the era of modern vaccinology, efficacious adjuvants and appropriate delivery 
systems for antigens are needed. In this context, nanotechnology offers some solutions 
(42). The need for safer and potent adjuvants resulted in the administration of an antigen 
within the nanoparticulated delivery systems (43). Owning to their specific features 
(size, shape and surface functionalities), a variety of nanoparticulated structures have 
been introduced as adjuvants and/or antigen delivery/presenting systems, opening the 
door to nanovaccinology. Among them, inorganic nanoparticles, liposomes, 
nanoemulsions, polymeric nanoparticles, self-assembled proteins, immunostimulating 
complexes and virus-like particles have been underlined as promising, and some of 
them have already been approved for human use (44, 45). In this section, 




3.1 Nanoemulsions as vaccine adjuvants 
As already described above in details, traditionally, aluminum salts are used as 
vaccine adjuvants with a view to boost the immune response in the presence of an 
antigen. Within the last two decades, nanoemulsion-based vaccine adjuvants have been 
shown to provide an alternative in terms of specific vaccine immunogenicity (46). 
Nanoemulsions represent heterogeneous liquid systems, consisting of oil and 
water, stabilized by a surfactant – an amphiphilic molecule. Surfactants can be defined 
by their hydrophilic-lipophilic balance (HLB) value, which gives information on their 
relative affinity for the both phases. Oil and water form two distinct compartments, one 
being dispensed in the other, forming nanodroplets. They can be water-in-oil or oil-in-
water (47, 48). These colloidal systems have been widely investigated as drug delivery 
systems for various administration routes: parenteral, dermal, oral, ocular, nasal (49–
52). In addition, nanoemulsions as excipient systems have been introduced as efficient 
modality for improved oral bioavailability of hydrophobic nutrients from food and food 
supplements (53, 54). Small average droplet size (generally in the range 50 - 300 nm), 
high solubilization capacity, good kinetic stability, existence of several different 
methods for their preparation from biocompatible ingredients are just some advantages 
that distinguish them among other colloidal systems (48, 55–57). 
As vaccine adjuvants in licenced vaccines, nanoemulsions were introduced in the 
1990s, when the first emulsion-based adjuvant was registered in Europe, as a product of 
the company Novartis (Basel, Switzerland) (58). Nanoemulsion-based adjuvants used 


















Table III  List of nanoemulsion-based adjuvants in licensed vaccines 
Tabela III  Lista emulzionih adjuvanasa u vakcinama odobrenim za humanu upotrebu 
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mineral oil,  
mannide monooleate 
(Prior to use, it is mixed with 
the conjugated antigen in the 
PBS, forming water-in-oil 
emulsion) 
< 1µm Seppic 2008 lung 
cancer  
 
More than eighty years ago, the adjuvant effect of mineral oil (in a water-in-oil 
emulsion) in combination with thermally killed mycobacteria cells was demonstrated by 
Freund, and this adjuvant was marked as Freund’s complete adjuvant (59). Afterwards, 
water-in-oil emulsions without the bacterial cells (Freund’s incomplete adjuvant) were 
used as adjuvants both in human and veterinary vaccines. Additionally, there was a little 
knowledge on their mechanism of action, even though it was suggested that they might 
act as depot systems. However, despite their indisputable efficacy, they were too 
reactogenic for routine use (45, 58).  
Acquired experience through the years pointed out some important characteristics 
that nanoemulsion-based adjuvants should possess, representing a milestone for further 
development. In general, efficacy of an adjuvant is determined by droplet size, oil 
content (oil-to-water ratio), droplet surface properties and viscosity (44, 61). It is 
preferred that oil phase is biodegradable, and surfactants should be recognized as safe 




lowering the oil content and shifting from water-in-oil to oil-in-water emulsions, which 
is followed by reduced viscosity, as well (43, 62). 
Moreover, subsequent refinement of the base materials has resulted in the new 
versions of water-in-oil emulsions. Among the ones undergoing clinical trial 
assessment, the MontanideTM emulsions can be underlined (products of the company 
Seppic (Paris, France) – especially for therapeutic vaccines. A vaccine against non-
small-cell lung cancer, the CimaVax EGF®, using this adjuvant technology, has already 
been licensed (60).  
3.1.1 Physicochemical properties of nanoemulsion-based adjuvants 
Physicochemical properties of nanoemulsion direct its efficacy and safety profile 
as adjuvant. This includes the type of the nanoemulsion, viscosity, droplet size and 
surface properties (63). 
The viscosity of a nanoemulsion is closely linked to the surfactant structure, its 
HLB value, and the ratio between the two phases. Too viscous formulations are not only 
difficult to be injected, but they also represent a safety issue. In general, oil-in-water 
nanoemulsions are characterized by lower viscosity. However, fluid water-in-oil 
nanoemulsions, with viscosity comparable to the viscosity of hydrophilic 
nanoemulsions, can be obtained if the stabilizers have optimized HLB value, 
corresponding to the type of selected oil (63). 
Even though there are crossing opinions, it is generally accepted that droplet size 
may be one of the key features. Smaller size enables sterile filtration, safer parenteral 
administration, gives rise to more stable formulations, and finally, it reduces chances for 
local inflammation (51, 61, 64, 65). Much effort has been put in order to identify the 
ideal size of an adjuvant to elicit the highest responses. However, this topic cannot be 
generalized, and findings are highly dependent on the specific class of adjuvants (64). 
Considering nanoemulsions, in animal studies with a set of different mice strains and 
various antigen types, it was noted that with increase in the droplet size of the 
nanoemulsion, the adjuvant efficacy increases. Contrastingly, nanoemulsions with 
smaller droplet size are inferior adjuvants, but with better safety profile (64). In the 
study of Shah et al. (66) it was highlighted that there was no benefit in reducing 
nanoemulsion droplet size below 160 nm – both for humoral and cellular immune 
response. Taken all together – efficacy and safety profile of nanoemulsion-based 
adjuvants, their stability and possibility to undergo sterile filtration, it may be concluded 
that „smaller is not always the better”. Nevertheless, size of the nanoemulsion droplets 
is affected by the components, their ratio in the nanoemulsion and the preparation 





3.1.2 Mechanism of action of nanoemulsion-based adjuvants 
On the one hand, nanoemulsions represent delivery systems, which protect the 
antigen and release it at the target site, enhancing the uptake of the antigen by the 
antigen presenting cells. On the other hand, they create an inflammation at the injection 
site and act as immunopotentiators, activating specific pathways (firstly of innate, and 
then of adaptive immunity) important for improved antigen processing (45, 60, 62). 
There is also a rational hypothesis that effective immune activation by nanoemulsion 
adjuvants may be, at least partially, mediated by the presence of surfactant on the oil 
droplets. However, it was proved that none of the nanoemulsion components solely can 
induce appropriate response, but the complete formulation is responsible for the effect 
(67). In the study of Giusti et al. (68), in in vitro and in vivo experiments, it was 
described that nanoemulsion droplets of an adjuvant are internalized by the lymph node 
cells. It is still unknown whether internalization in the target cell is required for immune 
response. However, it is suggested that surfactant molecules contribute to the uptake of 
nanoemulsion droplets, because they induce cell membrane perturbation, but this is 
probably not the only mechanism (66, 67).  
3.1.3 Antigen-adjuvant interactions 
There are several ways how nanoemulsions can be loaded with an antigen. 
Antigen can be entrapped in the core of the droplet (encapsulated), chemically 
conjugated, or it can simply be adsorbed to the surface (61). The main advantage of the 
entrapment is antigen protection. Also, surface of the droplet can be further decorated 
(PEGylation, targeting ligands) in order to provide precise delivery. Adsorption 
considers week interactions between the antigen and the droplet, which are mainly 
hydrophobic. It is critical in terms of antigen stability, but it is favorable as it needs less 
processing steps. Chemical conjugation may induce some changes on the antigen 
epitopes, but it can ensure that the antigen and the nanodroplet will reach the antigen 
presenting cell at the same time (45). Recent investigations have shown that soft matter 
particles, such as nanoemulsion droplets, are able to provide efficient immune response 
even if they are applied independently. Such finding highlighted the potential of 
nanoemulsions to act as immunopotentiators even in the situations with minimal 
association with the antigen, e.g. after simple mixing prior to the administration (45, 
69).  
3.1.4 Stability of nanoemulsion-based adjuvants 
Nanoemulsion stability is one of the primary concerns for the formulators. 
Instability can be a consequence of many factors, such as droplet flocculation, 
coalescence, creaming, Ostwald ripening, as well as chemical degradation, eventually 




oil, surfactants and aqueous components, along with processing conditions (70). In 
general, it is checked at 4°C, room temperature, and at 37 °C (63). 
Oil-in-water nanoemulsions usually show better stability compared to the water-
in-oil ones. For instance, stability of water-in-oil MontanideTM emulsions at room 
temperature is only several weeks (71). This certainly represents a drawback, but it is 
not the unique case in the context of pharmaceutical preparations, and it can be 
overcome by mixing the water phase with the surfactant-oil blend prior to the 
administration to the patients. Such approach is provided by through and appropriate 
selection of the oil, surfactants, and their ratio, so that the low-energy mixing can render 
the emulsion with desired properties. Contrastingly, stability of the oil-in-water 
nanoemulsions is far better - at room temperature it is more than 2 years (63, 71) 
3.1.5 Safety profile 
It is often very difficult to define the exact boundaries between 
immunostimulation and immunotoxicity, in order to reach the perfect balance of 
efficacy/safety and to comply with strict regulatory standards. Safety of nanoemulsion-
based adjuvants is related to the components, their origin and concentration in the 
formulation (70, 72). 
Traditional oil adjuvants may induce local and general reactions, such as 
granuloma, abscesses or fever. Indeed, highly purified non-mineral oils are well 
tolerated as they are rapidly metabolized and eliminated from the injection site, 
inducing weaker inflammation (63). Mineral oil stays longer at the injection site and it 
is eliminated by macrophages, and partially metabolized in fatty acids, triglycerides, 
phospholipids or sterols. Bollinger et al. (73) demonstrated that 30% of the mineral oil 
disappears during the first month and most of the oil found outside the injection site is 
in the liver and fatty tissues in the form of phospholipids and fatty acids. Stewart-Tull et 
al. (74) investigated the direct influence of the oil hydrocarbon chain length on the 
safety of adjuvants, pointing out that small chains are efficient, but induce local 
reactions, whereas longer chains (more than 14 carbon atoms) are safer, but less 
efficient. Nevertheless, due to the overall properties (biocompatibility, biodegradability, 
accessibility and immunostimulation ability), squalene is still the most widely used oil 
component in nanoemulsion-based adjuvants (70). 
The quality of surfactants, as inevitable components of nanoemulsion-based 
adjuvants, is also important. Up to now, licensed vaccine adjuvants are mostly based on 
the combination of sorbitan esters and polyoxyethylated soribitan esters, because, in the 
long run, they have shown to be safe for human use in parenteral formulation and very 
efficient emulsifiers, rendering stable emulsions with small droplet size. 
It should be underlined that development of any vaccine involves secondary 




investigate the influence of these procedures since they can have a major impact on the 
final vaccine formulations in terms of droplet size, size distribution, stability, and 
consequently immune responses (61). 
4. Microneedles for vaccine delivery into the skin 
In recent years, numerous disadvantages of parenterally formulated vaccines (e.g., 
cold storage and transportation system requirements, pain and discomfort during 
administration, hazardous waste, risk of needle-stick injuries and needle re-use, poor 
patient compliance and frequently, lack of potent immune response), have enforced the 
development of innovative technologies to deliver vaccine into the skin, primarily 
owing to excellent skin immunocompetence and ease of access (75–77). The skin has a 
dense network of antigen presenting cells – Langerhans cells and dermal dendritic cells, 
located in epidermis and dermis, respectively – that capture antigens, and upon a proper 
activation mature, migrate to the draining lymph nodes to activate T lymphocytes, 
inducing an adaptive immune response. Also, epidermal keratinocytes, when are in 
danger, produce a wide variety of cytokines and chemokines (e.g., TNF-α and IL-1β) as 
well as antimicrobial peptides, enhancing the maturation of antigen presenting cells and 
their migration to the lymph nodes (75, 78, 79). As a result, cutaneous vaccination has 
been shown to cause similar or better immune response compared to intramuscular 
injections, even, in some cases, lower antigen doses were used (due to a relatively 
sparse population of antigen presenting cells in the skeletal muscle compared to the 
skin) (76, 77). However, it should not be forgotten that the superficial skin layer, 
stratum corneum (SC), which protects the human body against entry of pathogen or 
toxic substances, represents tremendous physical barrier for efficient vaccine transport 
into the skin (76, 80). Among different strategies investigated to bypass this barrier 
resistance and to improve the transcutaneous immunization, considerable attention has 
been recently focused on microneedles.  
Microneedles are needle-like structures with lengths in the micrometer range 
(typically less than 1500 or 2000 µm) that can pierce the SC and create transient micro-
channels for the antigen delivery into the skin, but without disturbing the nerve endings 
and blood vessels in the inner viable skin layers (81, 82). Consequently, the application 
of microneedles provides the improved passage for the vaccine antigens towards the 
immune-competent skin layers in a minimally invasive and painless manner (75). In 
addition, due to the small size of needles, microneedles administration does not require 
the professional training and the healthcare personnel and simultaneously, reduces the 
risk of accidental needle-stick injuries (83). Most importantly, direct targeting of dense 
network of skin antigen presenting cells using microneedles generally produces higher 
humoral immune responses compared to conventional intramuscular injections (77). 




skin's abundant immune cell population using the coated Nanopatch microneedle array 
(>21,000/cm2 over 4 x 4 mm area; length 110 μm) significantly enhanced the resultant 
CD8+ T cell response when compared to standard, intramuscular delivery of both 
antigen-only and its adjuvanted form, implying its potentially usefulness for improving 
immunogenicity of vaccine against tuberculosis, HIV and malaria, for which the current 
vaccine approaches that induce only antibody response are inadequate (84). 
In addition, appropriately designed microneedles can generate the strong immune 
responses without any chemical-based adjuvant or with considerable lower adjuvant 
doses than required for the intramuscular injection, thus alleviating potential tolerability 
and safety issues (76, 84). Precisely, many of the commonly used vaccine adjuvants 
may not be compatible with the skin delivery approaches. For example, it was reported 
that alum, although the most frequently used vaccine adjuvant at the global market, 
when administered intradermally, might induce the serious side effects, such as 
persistent intradermal granulomas. On the other hand, advanced biphasic adjuvants 
(e.g., liposomes, oil-in-water emulsions), may not be sufficiently stable to withstand 
microneedle production procedure (coating and drying process) (76, 85). Hence, if 
necessary, a wide variety of substances including bacterial ADP-ribosylating exotoxins 
(Cholera toxin, Escherichia coli heat-labile toxin or their subunits), specific ligands of 
toll-like receptors CpG oligodeoxynucleotides, imiquimod, polyinosinic:polycytidylic 
acid (poly I:C), Quillaja saponins and others have been utilized in the combination with 
microneedles as immune enhancing additives to achieve the desirable immune 
responses (76). However, it should be kept in mind that skin permeability and the 
degree of vaccine delivery using microneedles can be also influenced by numerous 
parameters related to the physical properties of microneedle arrays (e.g., height, density, 
patch area and microneedle geometry) as well as to properties of applicator used for 
microneedle insertion into the skin (78, 86). For example, the length of the 
microneedles could be an important factor in the selective activation of specific antigen 
presenting cell population – shorter microneedles could predominately activate 
Langerhans cells in the epidermis, while longer could mainly affect dermal dendritic 
cells in the dermis (87). Also, the higher microneedle densities may be beneficial for 
improving the vaccine immunogenicity, since the skin treatment with microneedles 
induces the minor damage and cell death and consequently the release of damage-
associated molecular patterns, which initiate activation of innate immune response 
acting as „natural immune enhancer” (78). On the other hand, the proper applicator is 
neccesarry to ensure the effective, consistent and depth-controlled microneedle 
penetration into the skin, without the microneedle fracture. Various applicators have 
been developed (e.g., applicators based on hand-operated rotary application for single 
microneedle, vibration-based microneedle insertion devices, impact-insertion devices, 
etc.) and their selection directly depends on the geometry, sharpness and density of the 




Up to now, microneedles have been manufactured out of different materials, in a 
variety of shapes and sizes, depending on the application purpose. In general, all 
investigated microneedles can be classified in four major groups: solid, coated, 
dissolving and hollow microneedles (Figure 1) (82, 86). The next section deals with 
each type of microneedles in more detail, along with examples of their use in the 
vaccine development.  
 
 
Figure 1.  Schematic representation of different microneedle types and methods of antigen  
 delivery into the skin (adopted according to 82, 88, 89, 94) 
Slika 1.  Šematski prikaz različitih tipova mikroigala i metoda za isporuku antigena u  
 kožu (prilagođeno prema 82, 88, 89, 94) 
  
4.1 Types of microneedles 
Solid microneedles, as the simplest form of microneedles, were originally used for 
the skin pretreatment, in the „poke and patch” approach. After inserting and removing, 
solid microneedles form transient micropores in the skin surface, enabling the vaccine 
applied topically, on the treated area, to reach the immunogenic antigen presenting cells 
located in epidermis and dermis (82, 86, 89). The first solid microneedles were 
produced from silicon, but due to its fragile nature and risk of microneedle breaking into 
the skin, the various materials, such as metals (stainless steel, titanium, tantalum and 
nickel), ceramics, biodegradable and non-degradable polymers have been studied to 
ensure the sufficient mechanical strength of microneedles (82, 86). Detailed literature 




various vaccines into the mouse skin in vivo, such as vaccine for diphtheria, influenza, 
hepatitis B and malaria (79). Among the first, Ding et al. (90) observed that skin 
perforation with stainless steel microneedles (4×4 array on a polymer plate with the 
surface area of around 0.5 cm2; microneedle length of 300 µm) led to almost 1,000-fold 
increase in diphtheria toxoid -specific serum IgG levels after its topical application in 
mice, compared to intact skin. Furthermore, immune response was further boosted by 
co-administration of Cholera toxin, indicating that addition of appropriate adjuvant may 
lower antigen dose required. Interestingly, the same authors observed that microneedle 
pretreatment had no effect on the immune response to topically applied plain influenza 
subunit vaccine (91), suggesting that the immune response depends primarily on 
vaccine type, but also, to certain extent, on the administration procedure. Here, it is 
worth noting that solid microneedles were also used in the alternative „scrape and 
patch” approach, involving skin scrapping with blunt-tipped microneedles to generate 
microabrasions of the SC before the vaccine application onto the skin surface (79, 86). 
This approach was tested with Onvax™ microneedles (Becton Dickinson, USA) (an 
array of plastic microprojections with a height of ~200 µm) to improve delivery of a 
rabies vaccine in humans, but no protective immune responses were detected, probably 
due to its inefficient delivery into the epidermis (79, 86, 92). However, it should be 
noted that, despite some promising results, the popularity of solid microneedles for 
improving vaccine delivery into the skin has declined in recent years, predominately 
due to cumbersome two-step administration process, inconsistent results and 
consequently, increased interest in other types of microneedles (79, 82, 93).  
Advancement on classical solid microneedles was development of „coat and 
poke” approach, which involves pre-coating of microneedle arrays by suitable, water-
soluble vaccine formulation that rapidly dissolves upon microneedles insertion into the 
skin (before the removal from the skin). In this way, solid microneedles are utilized not 
only to perforate the skin, but also, as vehicles to carry and deliver antigens directly into 
this skin, offering simplified (one-step) vaccination procedure (79, 82, 86, 94). 
However, it should be kept in mind that small antigen dose (typically less than 1 mg) 
can be administered via coated microneedles, due to the limited dimensions of 
microneedles shaft and tip – thick coatings are generally accompanied with a very low 
skin delivery efficacy because of a reduced sharpness of microneedle arrays (82, 86). 
Composition of coating solution depends on the nature and type of antigen investigated 
and commonly includes viscosity enhancer (e.g., carboxymethylcellulose (CMC), 
methylcellulose) to achieve sufficient thickness of coating layer, stabilizing saccharide 
(e.g., trehalose, sucrose) to retain activity of antigen during drying/storage and 
surfactant (e.g., poloxamers) to decrease the surface tension and thus to assure uniform 
coating efficiency (95, 96). Additionally, Choi and co-workers (97) observed that 
addition of viscosity enhancers was necessary to reduce the osmotic stress (caused by 




influenza virus during the microneedle coating. Furthermore, the presence of viscosity 
enhancer improved systemic immune response and ensured better protection against the 
viral challenge (95, 97). On the other hand, owing to inherent stability and viscosity, 
DNA vaccines can be coated onto microneedles without stabilizers and viscosity 
enhancers (98). For example, Song et al. (98) observed that metal microneedles (length 
of 750 µm) coated with solution of plasmid DNA vaccine encoding the influenza 
hemagglutinin (excipient free coatings) induced higher humoral and cellular immune 
responses as well as better protective immunity compared to conventional i.m. 
immunization. Alternatively, in order to improve the coating efficiency, it was proposed 
to perform the pre-coating of microneedle surface with SiO2, polylactic-co-glycolic acid 
(PLGA) or polyvinylpyrrolidone (PVP) or by the formation of polyelectrolyte coatings 
with microencapsulation properties (e.g., polydi(carboxylatophenoxy)phosphazene, 
chitosan and CMC). Interestingly, it was observed that some of these pre-coatings were 
capable to improve the vaccine stability and exhibit adjuvant effect (85, 86). Finally, it 
is worth mentioning that although coated microneedles were successfully used to 
deliver various antigens into the skin of different animal models (e.g., influenza, human 
papillomavirus, West Nile virus, rotavirus, herpes simplex virus, hepatitis B and C, 
bacillus Calmette-Guerin, measles and polio viruses), inducing better or equal immune 
response compared to parenteral needle-based immunization, literature review revealed 
no clinical trials pertaining to vaccine delivery via coated microneedles (79). 
Opposite to the solid/coated microneedles, dissolving microneedles consist of 
water soluble or biodegradable materials (e.g., polymers, sugars), enabling the antigen 
encapsulation within the microneedle matrix. After insertion into the skin, dissolving 
microneedles completely dissolve/degrade into the skin, simultaneously releasing 
incorporated antigen („poke and release” approach) (82, 86). Consequently, this 
approach offers numerous distinct advantages such as improved antigen stability, self-
administration and absence of biohazardous sharp waste and safe disposal of remaining 
part (78, 79, 82, 86). However, there are also important challenges in the microneedle 
preparation which limit their widespread use, such as antigen wastage (due to low 
volume filling of the microcavities used for micromolding preparation procedure), 
insufficient antigen and adjuvant loading (due to low volumes of microneedle tips), 
antigen degradation and sterility (78, 86). The dissolving microneedles have been 
usually fabricated from sodium hyaluronate and CMC, as inactive materials approved 
by FDA for parenteral drug products, but also from other polymers (e.g., 
poly(vinylalcohol), PVP, methylvinylether-co-maleic anhydride) and low molecular 
weight sugars (e.g., maltose, trehalose). Biodegradable polymers such as PLGA, 
polylactic acid and polyglycolic acid are not advisable as the matrix material due to 
their slow dissolution rate in skin and a fabrication method involving high temperatures 
and organic solvents (78). Up to now, different vaccine types, ranging from proteins and 




viruses, have been encapsulated in the microneedle matrix by direct dispersing into 
polymer, or by incorporating into nanoparticles or into a cross-linked structure to boost 
immune response. Numerous studies have shown that dissolving microneedles, 
depending on the antigen type, induced comparable or better humoral and/or cellular 
immune responses than s.c., i.m. or traditional i.d. injection of the same antigen dose. 
Furthermore, a considerable improvement of immune response was observed when 
adjuvants, compatible with skin administration route (e.g., CpG, poly(I:C), Quil-A, 
monophosphoryl lipid A and imiquimod) were added (78). Finally, it is important to 
emphasize that dissolving microneedles represent a relatively new vaccine delivery 
platform and there are no authorized products on the market. However, there are a few 
clinical studies examining (i) the effect of microneedle patch on local skin reactions, 
reliability of use and acceptability to patients (99, 100) as well as (ii) efficacy of novel 
transcutaneous influenza vaccine based on dissolving microneedles containing trivalent 
influenza hemagglutinins relative to subcutaneous injections of each influenza antigen 
(101). Obtained results suggested that investigated microneedle patches were generally 
well tolerated in the skin, with only mild erythema localized to treated site that resolved 
fully within seven days (78, 99). Furthermore, administration of influenza vaccines to 
human subjects via dissolving microneedles induced high level of immunity, proving 
that dissolving microneedles are promising for practical use as an easy and effective 
method to replace conventional injections systems (100). 
Hollow microneedles have an empty space inside and hole at the tip, enabling the 
passive diffusion, or alternatively, active pressure-driven flow of a liquid formulation 
into the skin („poke and flow” approach). The latter can be achieved by combining 
microneedles with external pressure device, such as syringe, pump, or pressurized gas 
(86). Hollow microneedles have been commonly made from silicon, glass, polymer and 
metal, in two designs, as a single microneedle (mimicking the conventional hypodermic 
needle) and an array of multiple microneedles. Increase in the number of microneedles 
per patch enables the simultaneous application of vaccine formulation over the wider 
skin area, thus potentially enhancing the likelihood of lymphatic uptake of presented 
antigens (86). The important advantage of this approach lies in a possibility of using the 
existing injectable formulations, but there are no opportunities to administer dry-state 
vaccine formulations which permit to improve the antigen stability and avoid cold 
storage and transportation system. Additional limitation of this approach is relatively 
low diffusion rate that can be potentially overcome by partial retraction or by adding 
hyaluronidase to the infusion solution (to degrade the hyaluronic acid within skin 
collagen fibers) (86, 102). Also, hollow microneedles are associated with less patient 
convenience compared to other microneedle types (82, 94). Hollow microneedles have 
been used to immunize human volunteers with polio and influenza vaccines, but also 
other antigens have been successfully delivered into the skin of various animal models 




available hollow microneedle devices: (i) Soluvia™ Microinjection System (Becton 
Dickinson, USA), consisting of single silicon needle (length 1500 µm) coupled with a 
pre-fillable injection system, has been marked for delivery of influenza vaccination 
(other trade names are Intanza®; IDflu® and Fluzone Intradermal® by Sanofi Pasteur) 
(ii) MicronJet® (NanoPass, Israel), consisting of four hollow silicon microneedles 
(length 600 µm) arranged on a plastic adaptor for the use with a standard syringe, has 
also obtained FDA approval (iii) 3M™ Hollow Microstructured Transdermal System 
(hMTS) (3M, USA) comprising 12 polymer microneedles (length 1500 µm), is intended 
for clinical studies (81, 88, 103).  
To conclude, in the era of modern vaccinology, it is a must to define optimal 
balance between efficacy and safety of an adjuvant, in order to provide potent and safe 
vaccines. Relying on already established approaches, some innovative adjuvants and 
vaccine delivery systems are presented in this work. It remains that intense 
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U doba savremene vakcinologije, ograničena imunogenost većine korišćenih antigena 
podstakla je primenu različitih adjuvanasa u formulacijama vakcina radi postizanja željenog 
imunskog odgovora. Mineralni adjuvansi na bazi aluminijuma su istorijski najčešće korišćeni 
imunostimulansi u vakcinama i smatraju se generalno bezbednim za humanu upotrebu. Značajni 
napredak na polju sinteze, kontrole strukture i funkcionalnog dizajna neorganskih 
(nano)materijala uslovio je povećano interesovanje za primenom inovativnih adjuvanasa kao što 
su gline, mezoporozne silika nanočestice, nanočestice cink-oksida, gvožđe oksida i gvožđe 
hidroksida, i dr. Sa druge strane, uočava se i sve veće interesovanje za primenom specifičnih 
nanonosača antigena, kao što su nanoemulzije, kako bi se antigeni zaštitili od preuranjene 
proteolitičke degradacije i/ili poboljšala njihova imunogenost, olakšavanjem preuzimanja i 
obrade od strane antigen-prezentujućih ćelija. Takođe, brojni istraživački napori tokom 
poslednjih nekoliko godina usmereni su ka razvoju inovativnih tehnologija za isporuku antigena 
u kožu (kao što su mikroigle) radi poboljšanja efikasnosti vakcinacije uz istovremeno povećanje 
adherence pacijenata, posebno u pedijatrijskoj populaciji (neinvazivan ili minimalno invazivan 
način primene). Otuda, u ovom preglednom radu dat je detaljan pregled karakteristika svakog 
od navedenih pristupa za poboljšanje efikasnosti vakcina, sa posebnim osvrtom na primere 
njihove primene u formulacijama vakcina i faktore koji određuju efikasnost i bezbednost. 
 
Ključne reči: formulacija vakcina, adjuvansi, mineralni adsorbenti,  
  nanoemulzije, mikroigle 
 
